PRECLINICAL IN VITRO AND IN VIVO INVESTIGATION OF THE FIRST-IN-CLASS SELECTIVE SIK2/SIK3 INHIBITOR GLPG3970 IN EXPERIMENTAL MODELS OF IBD

Anna Pereira-Fernandes  1     Stéphanie Lavazais  2     Carole Delachaume  2     Michael Drennan  2     Didier Merciris  2     Nancy Agten  2     Christophe Peixoto  2     Anne Gigout  2     Nicolas Desroy  2     David AMANTINI  2     Steve De Vos  2    
1 Galapagos NV, Mechelen, Belgium
2 Galapagos SASU, Romainville, France

Topic
Disease Mechanisms, IBD, Immunology

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing